DOCSLIB.ORG

349 © Springer Nature Switzerland AG 2020 A. Tosti Et Al. (Eds.), Hair

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
349 © Springer Nature Switzerland AG 2020 A. Tosti Et Al. (Eds.), Hair Index A diagnosis, 237 Abatacept, 118, 344 management, 237, 238 Acitretin, 183, 184 phototherapy, 240 Acne keloidalis nuchae (AKN), 18–20, 155, poor prognostic factors, 237 156 systemic treatment, 239 Acute telogen effluvium, 125, 129 topical and intralesional treatment Adalimumab, 185, 186 options, 238 Adams-Oliver syndrome, 242 impregnate a cotton swab, 28 Adjuvant therapy, 121 intralesional corticosteroid therapy, African hair, 262 111, 112 African sensitive hair, 263 intralesional steroid dosing, 112 5 alfa reductase inhibitors, 49 intramuscular steroid therapy, 114 Aloe vera, 169 intravenous steroid therapy, 114 Alopecia areata (AA), 21, 81, 85, 237, 247, JAK inhibitors, 119 300, 301, 324, 328, 329 low/no efficacy, 122 abatacept, 344 microneedling in, 40 adjuvant therapy, 119–121 mild dermatitis, 28 affecting beard/eyelashes/eyebrows, 111 modified DPCP protocol, 27 allergic reaction, 28, 31 oral JAK inhibitors, 342, 343 anthralin, 116 oral steroid therapy, 114 apremilast, 344 patch test, 27 BMD1141, 343, 344 patient’s reaction, 29 BNZ-1, 343 phototherapy and excimer laser, 116–118 in children and adults treatment, 110 phototherapy and laser therapy, 117 children and pregnant women, 33, 34 prostaglandin F2a analogs, 116 corticosteroid-sparing agents, 115 SADBE, application of, 25, 30 different corticosteroid-sparing agents, 114 scalp micropigmentation, 110 DMARD, 114, 115 schedule visits, 29 DPCP, 25, 343 sensitize patients, 27 dupilumab, 345 side effects, 31, 33 efficacy assessment, 31 suitable therapeutic regimen, 109–111 evidence-based treatment options, 120, 121 systemic steroids + corticosteroid-sparing/ feedback about allergic reaction, 29 DMARD agents, 115 fumaric acid, 344 systemic therapy, 113 hair loss targeted therapeutics, 118 course of, 237 topical immunotherapy, 25, 30, 115, 116 © Springer Nature Switzerland AG 2020 349 A. Tosti et al. (eds.), Hair and Scalp Treatments, https://doi.org/10.1007/978-3-030-21555-2 350 Index Alopecia areata (AA) (cont.) 5-alpha reductase inhibitor, 92 topical JAK inhibitors, 343 dosage regimen, 93, 94 topical steroid therapy, 111 safety and sexual side effects, 92, 93 tralokinumab, 345 in women, 94 treatment diagram, 26 spironolactone, 97 treatment response, 33 Antihistamines, 120, 223 treatment schedule, 29 Antimalarials (hydroxychloroquine), 145 vitamins, 79, 80, 120 Antivirals, 120 Anagen effluvium, 324 Apira Science Revage 670, 57 Androgenetic alopecia (AGA), 2, 10, 53, 78, Aplasia cutis congenita, 242 296–298, 324, 327, 329–331 Apple-condensed tannins (ACT), 226 adjuvant therapies and procedures, 103 Apremilast, 118, 183–185, 344 hair transplantation, 102 Arnica, 222 laser and light sources, 102 Aromatherapy, 119, 120 PRP injections, 102 Artificial hair implants, 280, 281 androgen-independent therapies, 98, 99 Atopic dermatitis, 227 antiandrogen therapies (see Antiandrogen Automatic devices, 36 therapies) finasteride, 92 causes of hair consultation, 91 B CB-03-01, 340 Baldness, 330 emerging clinical therapies Baricitinib, 118, 342 cortexolone 17α-propionate, 101 Benzoyl peroxide, 211 oral minoxidil, 101 Benzyl alcohol, 203 setipiprant, 101 Betamethasone, 18 topical 5-alpha-reductase inhibitors, Bexarotene, 238 100 11-B-hydroxysteroid hydroxygenase, 222 WNT/β-catenin pathway, 102 Bimatoprost, 99 female androgenetic alopecia, 95 Biofibre®, 280 female pattern hair loss (FPHL), 91 Biologic agents finasteride and topical minoxidil, 94 adalimumab, 185, 186 FPHL, 91, 104, 105 brodalumab, 186 male androgenetic alopecia, 93 certolizumab pegol, 187 male pattern hair loss, 337 etanercept, 185 MPHL, 91, 104 guselkumab, 187 multifactorial and polygenetic, 91 infliximab, 185 PGF2 analog, 338 itolizumab, 187 prevalent condition, 91 ixekizumab, 186 setipiprant, 339 secukinumab, 186 sexual side effects of oral finasteride, 338 tildrakizumab, 187 SM04554, 340 ustekinumab, 186 topical finasteride, 341 BiologicsMD, 343 topical JAK inhibitors, 340, 341 Biotin, 78, 327 topical minoxidil and finasteride, 94 Bisabolol, 166 Anthralin, 116 Bitemporal thinning, 126 Antiandrogen therapies Bleached hair, 256 cyproterone acetate, 98 Blow dryer, 281 dutasteride BMD1141, 343, 344 5-alpha-reductase inhibitor, 96 BNZ-1, 343 dosage regimen, 96 Bolanča, 45 hyperandrogenism, 97 Borage oil, 169 safety and sexual side effects, 96 Botulinum toxin, 226–228 in women, 97 Brauer’s nevus, 241, 242 finasteride Brazilian keratin treatment (BKT), 259, 287 Index 351 Brodalumab, 185, 186 Digital videodermatoscopes, 2 Bubble hair, 246 Dihydrotestosterone (DHT), 92, 329 Butorphanol, 223 4-dimethylaminocinnamaldehyde, 12 Diphenhydramine, 223 Diphenylcyclopropenone (DPCP), 25 C Discoid lupus erythematosus (DLE), 140, 147, Calcineurin inhibitors, 149 148, 313, 314 Calcipotriene (Calcipotriol), 181 Disease-modifying antirheumatic drug Calcitonin gene-related peptide (CGRP), 221 (DMARD), 114, 115 Calcitriol, 181 Dissecting cellulitis (DSC), 9, 150–152, 308, Cannabinoid, 221 309 Cap/helmet-shaped devices, 57 Down syndrome, 241 Catagen hairs, 12 Doxepine, 225 CB-03-01, 340, 341 Doxycycline, 141 Central centrifugal cicatricial alopecia Dronabinol, 224 (CCCA), 8, 148–150 Dry hair, 257, 258, 262, 327 Certolizumab pegol, 185, 187 Ducray Extra-Doux shampoo, 257, 258, 260 Cervantes, 44 Ducray Sabal Shampoo, 257 Cervical and occipital lymphoadenopathy, 31 Dupilumab, 118, 345 Cesare Ragazzi Laboratories, 267 Dutasteride, 304 Chandrashekar, 40 Dynamic or sequential trichoscopy, 296 Chinese herbal medicine, 226 Dyson Airwrap™, 281 Chronic telogen effluvium, 125, 129, 130 Cicatricial alopecias, 331 Cicatricial or scarring alopecias, 331 E Ciclopiroxolamine, 210 Ebastine, 119 Ciclosporin, 189 Ectodermal dysplasias, 242 Climbazole, 166 Ehrenfest, D., 41 Clindamycin, 211 El Taieb, 45 CNC® Hair Prosthesis, 268 Epidermolysis bullosa, 242 CO2 laser, 52 Erbium-glass laser, 49, 52 Coal tar, 167, 182 Erythromycin, 211 “Cold” X5 HairLaserTM, 57 Etanercept, 185 Cognitive-behavioral therapy, 241 Evaluate treatment response Conditioners, 255, 256 adding adjuvant treatments, 291 Congenital triangular alopecia, 241, 242 changing therapy, 291 Contact dermatitis, 312, 313 cicatricial alopecia, 291 Cortexolone, 101 increasing/decreasing treatment dose, 291 Corticosteroids, 165, 166 instruments Corynebacterium spp., 211 cross-section trichometer, 292 Cotton swab, 28 dynamic/sequential trichoscopy, 296 Crepe wool hair, 275 FFASI, 293, 294 Cromolyn sodium, 223 frontal fibrosing alopecia severity Custom-made caps, 267 score, 294 Cutaneous atrophy, 18 global photography, 295, 296 Cyclosporine, 114, 183 handheld dermoscopy, 292 Cyproterone acetate, 98 HSVS, 293 lichen planopilaris activity index, 295 phototrichogram, 293 D SALT score, 295 Dandruff, 331 Dr. Tosti’s scale, 295 Demipermanent dyes, 288 videodermoscopy, 292 Dermoscopy, 1 prescribed therapy, 291 Dhurat, 38 scalp diseases 352 Index Evaluate treatment response (cont.) G alopecia areata, 300, 301 GABA analogues, 225 androgenetic alopecia, 296–298 Gabapentin, 225 contact dermatitis, 312, 313 Gamma-linolenic acid (GLA), 169 discoid lupus, 313, 314 German chamomile, 222 dissecting cellulitis, 308, 309 Global photography, 295, 296 FFA, 302–304 Glutathione peroxidase, 80 folliculitis decalvans, 307, 308 Gluteal atrophy, 113 hair transplant, 317–319 Glycyrrhetinic acid, 166 lichen planopilaris, 304–306 Griseofulvin, 201, 205, 206, 209, 235 pediculosis, 316 Grow long hair, 328 psoriasis, 309, 310 Guselkumab, 185, 187 seborrheic dermatitis, 311, 312 Gynecomastia, 92 telogen effluvium, 298–300 tinea capitis, 315, 316 Excimer laser therapy, 58, 240 H Extra-doux shampoo, 262 Hair bulbs, 12, 13 Eyebrow loss, 145 Hair crayons, 279 Eyebrow microblading, 280 Hair cutting, 323 Eyebrows, 324 Hair dyes, 254 Eyelashes, 324 adverse events, 289 Ezetimibe/simvastatin, 119, 120 bleaching, 289 Brazilian keratin treatment, 287 demipermanent and permanent F colors, 288 Facial papules, 143, 145 modify natural hair color, 288 Farid, 39 restore pigmentation, 288 Female pattern hair loss (FPHL), 69, 80 straightening and permanent waving, Fexofenadine, 119 285, 286 Fibrosing alopecia, 7, 146 temporary and semipermanent Fibrosing alopecia in a pattern distribution colors, 288 (FAPD), 140, 145 tips to avoid hair damage, 287 Finasteride, 39, 53, 58, 304 Hair extensions, 270, 271, 273, 274 Flavin adenine dinucleotide (FAD), 78 Hair fibers, 278 Flavin mononucleotide (FMN), 78 Hair follicle, 324 Fluconazole, 168, 172, 208–210 Hair graying, 325 Follicular unit (FU), 65 Hair growth, 323 Follicular unit excision (FUE), 66, 72 Hair iron, 281 Folliculitis decalvans (FD), 8, 18, 20, 140, Hair loss, 324, 327 152–154 different causes, 327 Fotofinder, 292 diffuse alopecia, 247 Fractional thermolysis (FT), 49 female pattern, 330 Frontal fibrosing alopecia (FFA), 2, 7, 18, 19, lack of clinical trials, 233 48, 57, 140, 142–145, 302–304 male pattern, 330 Frontal fibrosing alopecia severity index patchy alopecia (FFASI), 293, 294 AA (see Alopecia areata (AA)) Frontal fibrosing alopecia severity score, 294 aplasia cutis congenita, 242 Fuconazole, 205 congenital triangular alopecia, Fumaric acid, 344 241, 242 Fumaric acid esters (fumarates), 188 hair shaft disorders, 243 Fusidic acid, 211 TC (see Tinea capitis (TC)) Index 353 risks versus benefits of therapy, 233 Hair washings, 323 Hair prosthesis, 120 Hair-Contact®, 274 hair extensions, 270, 271, 273, 274 Hairline, 330 hairpieces, 269, 270 HairMax® LaserBand, 54 integration wigs, 269 HairMax® LaserComb, 54 patchy hair loss, 274, 275 Hairpieces, 269, 270 wigs Hair-shedding visual scale (HSVS), 293 caps,
Load more

Recommended publications
  • WHO Drug Information Vol
    WHO Drug Information Vol. 24, No. 4, 2010 World Health Organization WHO Drug Information Contents WHO Prequalification Sitaxentan: worldwide withdrawal 307 Programmes Sibutramine: suspension of sales 307 Sibutramine-containing medicines: WHO Prequalification of Medicines withdrawal 308 Programme: survey of service Testosterone transdermal patch: quality provided to manufacturers 293 withdrawal of extension of WHO initiates pilot prequalification of indication application 308 active pharmaceutical ingredients 297 Aliskiren/valsartan: withdrawal of New on-line database for WHO marketing authorization application 308 prequalified vaccines 298 Mometasone furoate/formoterol fumarate: withdrawal of marketing Safety and Efficacy Issues authorization application 309 EMA and US FDA extend confidentiality H1N1 influenza vaccine: narcolepsy 299 arrangements indefinitely 309 Statins: interstitial lung disease 299 Tocilizumab: risk of fatal anaphylaxis 300 Recent Publications, Pioglitazone: potential bladder cancer 301 Information and Events Angiotensin receptor blockers and US Government to share patents with cancer: safety review 301 Medicines Patent Pool 310 GnRH agonists, diabetes and cardio- Clinical trials and global medicines vascular disease 301 development 310 Gadolinium-based contrast agents: Evaluation of future nanomedicines 311 kidney dysfunction 302 Reporting on opioid inaccessibility 311 Lamotrigine: aseptic meningitis Tinzaparin sodium: renal Impairment in elderly 303 Consultation Documents Tamoxifen: drug interactions involving The
    [Show full text]
  • 2018 Medicines in Development for Skin Diseases
    2018 Medicines in Development for Skin Diseases Acne Drug Name Sponsor Indication Development Phase ADPS topical Taro Pharmaceuticals USA acne vulgaris Phase II completed Hawthorne, NY www.taro.com AOB101 AOBiome acne vulgaris Phase II (topical ammonia oxidizing bacteria) Cambridge, MA www.aobiome.com ASC-J9 AndroScience acne vulgaris Phase II (androgen receptor degradation Solana Beach, CA www.androscience.com enhancer) BLI1100 Braintree Laboratories acne vulgaris Phase II completed Braintree, MA www.braintreelabs.com BPX-01 BioPharmX acne vulgaris Phase II (minocycline topical) Menlo Park, CA www.biopharmx.com BTX1503 Botanix Pharmaceuticals moderate to severe acne vulgaris Phase II (cannabidiol) Plymouth Meeting, PA www.botanixpharma.com CJM112 Novartis Pharmaceuticals acne vulgaris Phase II (IL-17A protein inhibitor) East Hanover, NJ www.novartis.com clascoterone Cassiopea acne vulgaris Phase III (androgen receptor antagonist) Lainate, Italy www.cassiopea.com Medicines in Development: Skin Diseases ǀ 2018 Update 1 Acne Drug Name Sponsor Indication Development Phase CLS001 Cutanea acne vulgaris Phase II (omiganan) Wayne, PA www.cutanea.com DFD-03 Promius Pharma acne vulgaris Phase III (tazarotene topical) Princeton, NJ www.promiuspharma.com DMT310 Dermata Therapeutics moderate to severe acne vulgaris Phase II (freshwater sponge-derived) San Diego, CA www.dermatarx.com finasteride Elorac severe nodulocystic acne Phase II (cholestenone 5-alpha Vernon Hills, IL www.eloracpharma.com reductase inhibitor) FMX101 Foamix moderate to severe
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Crth2: Can Residence Time Help ?
    CRTh2: Can Residence Time Help ? RSC-SCI Cambridge Medicinal Chemistry Symposium Churchill College, Cambridge 8-11 September 2013 Rick Roberts Almirall Introduction Paul Ehrlich, The Lancet (1913), 182, 445 “A substance will not work unless it is bound” 100 years on: “What a substance does may depend on how long it is bound” 2 In a nutshell …. Introduction “Applications of Binding Kinetics to Drug Discovery” D. Swinney, Pharm. Med. (2008), 22, 23-34 3 Energetic concept of Residence Time kon Standard model [R] + [L] [RL] k unbound off bound Energy ‡ Binding process (kon) is (R·L) determined by the energy barrier Ea E Ligand concentration a Unbinding process (koff) is determines the number of Ed determined by the energy attempts to get over this barrier Ed barrier [R] + [L] G = Ed -Ea [RL] Reaction coordinate Potency (Ki) is determined by the difference in these energies koff Ki = kon 4 K , k , k i on off -1 -1 kon M s Potency (nM) vs kon vs koff Very fast association 108 10 1 0.1 0.01 0.001 107 100 10 1 0.1 0.01 0.001 fast association 106 1000 100 10 1 0.1 0.01 0.001 105 10 M 1000 100 10 1 0.1 0.01 0.001 slow association 104 10 M 1000 100 10 1 0.1 0.01 Very slow association 103 10 M 1000 100 10 1 0.1 “inactive” 102 10 M 1000 100 10 1 10 10-1 10-2 10-3 10-4 10-5 10-6 10-7 s-1 koff Energy A simple binding measurement gives no clue to how fast the association and dissociation are (R·L)‡ Very slow associating compounds that are very slow dissociating (R·L)‡ slow associating compounds that are slow dissociating Are all fast associating compounds
    [Show full text]
  • Solubility Challenges: Unlocking a Drug’S Potential JULY 2015 Pharmtech.Com
    JULY 2015 Volume 39 Number 7 Volume 39 Number 7 Cleaning Stability Tablet Count PLUS: Validation of Biologics in Packaging PHARMACEUTICAL TECHNOLOGY Solubility Challenges: Unlocking a Drug’s Potential JULY 2015 2015 JULY PharmTech.com PEER-REVIEWED Using In-Situ Gelling to Optimize Opthalmic Drug Delivery DRUG DELIVERY OPERATIONAL EXCELLENCE API SYNTHESIS & MANUFACTURING Targeting Drugs to the Colon Data Integrity Continuous API Synthesis magentablackcyanyellow ES639585_PT0715_cv1.pgs 07.07.2015 20:54 ADV magentablackcyanyellow ES639144_PT0715_CV2_FP.pgs 07.06.2015 20:46 ADV INTRODUCING Vion IMS QTof When you’re up against complex samples, sometimes resolution and accurate mass aren’t enough to give you all the information you need. Enter Vion IMS QTof with Collision Cross Section (CCS). A new mass spectrometer that brings ion mobility to the benchtop like never before. Now the analytes you didn’t know were there have nowhere to hide. To learn more, visit waters.com/VION PHARMACEUTICAL n HEALTH SCIENCES n FOOD n ENVIRONMENTAL n CHEMICAL MATERIALS magentablackcyanyellow ES639166_PT0715_003_FP.pgs 07.06.2015 20:46 ADV EDITORIAL SALES Editorial Director Rita Peters [email protected] Publisher Mike Tracey [email protected] Senior Editor Agnes Shanley [email protected] Director of Sales Paul Milazzo [email protected] Managing Editor Susan Haigney [email protected] Mid-West Sales Manager Irene Onesto [email protected] Science Editor Adeline Siew, PhD [email protected] East Coast Sales Manager Joel Kern [email protected]
    [Show full text]
  • Prostanoid Receptors (Version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database
    IUPHAR/BPS Guide to Pharmacology CITE https://doi.org/10.2218/gtopdb/F58/2019.5 Prostanoid receptors (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database Richard M. Breyer1, Lucie Clapp2, Robert A. Coleman3, Mark Giembycz4, Akos Heinemann5, Rebecca Hills6, Robert L. Jones7, Shuh Narumiya8, Xavier Norel9, Roy Pettipher10, Yukihiko Sugimoto11, Mohib Uddin12, David F. Woodward13 and Chengcan Yao6 1. Vanderbilt University, USA 2. University College London, UK 3. Pharmagene Laboratories, UK 4. University of Calgary, Canada 5. Otto Loewi Research Center (for Vascular Biology, Immunology and Inflammation), Austria 6. University of Edinburgh, UK 7. University of Strathclyde, UK 8. Kyoto University Faculty of Medicine, Japan 9. Laboratory for Vascular Translational Science, France 10. Atopix Therapeutics Ltd, UK 11. Kumamoto University, Japan 12. AstraZeneca, Sweden 13. Allergan plc, USA Abstract Prostanoid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Prostanoid Receptors [659]) are activated by the endogenous ligands prostaglandins PGD2, PGE1, PGE2 , PGF2α, PGH2, prostacyclin [PGI2] and thromboxane A2. Measurement of the potency of PGI2 and thromboxane A2 is hampered by their instability in physiological salt solution; they are often replaced by cicaprost and U46619, respectively, in receptor characterization studies. Contents This is a citation summary for Prostanoid receptors in the Guide to Pharmacology database (GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here under database links. GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them.
    [Show full text]
  • Is It Too Late? PAGE 58
    MOST TRUSTED & MOST READ Is It Too Late? PAGE 58 On Board the HowtoSpot Friendship Online Bus Love Scams PAGE 26 PAGE 30 6 Silent Diabetes Symptoms You’re Missing PAGE 16 He’sGotaGun! The Hijack on Baldness Flight 918 Business PAGE 50 PAGE 116 Kindness of Strangers ................................. 12 News Worth Sharing ..................................130 1 FREE % PLUS 40OFF ISSUE + A SPECIAL FREE GIFT Every issue of Reader’s Digest offers only the best original writing on issues that MOST TRUSTED& matter to you. MOST READ Real-life dramas and uplifting stories, amazing NG THE health discoveries and human adventure. PANDA Long reads mixed Is It TooPAGE Late? 58 with short stories. HowtoSpot PLUS exclusive On Board the Online book excerpts. Friendship Bus Love Scams PAGE 30 PAGE 26 + Only $48 for 12 issues. 6 That’s just $4.00 per issue, Silent Diabetes instead of $6.50 at retail Symptoms You’re Missing PAGE 16 + EXTRA ISSUE FREE to He’sGotaGun! The enjoy with our compliments Baldness Hijack on DELIVERY included Business + Flight 918 PAGE 116 every month PAGE 50 12 ................................. PLUS a special free gift Kindness of Strangers + ..................................130 News Worth Sharing TO ORDER: ASIA: rdasia.com/get-the-magazine AUSTRALIA: readersdigest.com.au/subscribe NEW ZEALAND: readersdigest.co.nz/subscribe Contents FEBRUARY 2018 Heart 26 FRIENDSHIP BUS Kiwi filmmaker Julie Zhu takes a bus trip with grandparents who bond over bargains. INDIA HENDRIKSE FROM WWW.NOTED.CO.NZ Crime Watch 30 LONELY HEART SCAMS How online criminal networks defraud lonely people with false promises of romance and love. HELEN SIGNY Nature 40 THE TREES ARE TALKING Nature is networking in the forest via the ‘wood wide web’.
    [Show full text]
  • The Management of Seborrheic Dermatitis 2020: an Update
    Review Article The management of seborrheic dermatitis 2020: An update Sandra Widaty1, Kusmarinah Bramono1, Muhammad Yulianto Listiawan2, Ariyati Yosi3, Eliza Miranda1, Githa Rahmayunita1, Herwinda Brahmanti4, Henry W Lim5 1Department of Dermatology and Venereology, Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia 2Department of Dermatology and Venereology, Faculty of Medicine Universitas Airlangga, Dr. Soetomo General Hospital, Surabaya, Indonesia 3Department of Dermatology and Venereology, Faculty of Medicine Universitas Sumatera Utara, H. Adam Malik General Hospital, Medan, Indonesia 4Department of Dermatology and Venereology, Faculty of Medicine Universitas Brawijaya, Dr. Saiful Anwar General Hospital, Malang, Indonesia 5Department of Dermatology, Henry Ford Hospital, Detroit, Michigan, USA Email: [email protected] Abstract Background: Seborrheic dermatitis (SD) is a chronic relapsing dermatitis manifesting in the seborrheic area, affecting infants or adults. In Indonesia, the prevalence of SD is 0.99–5.8% of all dermatology cases from 2013 to 2015. SD has been known to be a prominent manifestation among HIV patients, but there is an increasing trend in the general population. Therefore, in 2017, the Indonesian Society for Dermatology and Venereology proposed a consensus for the management of SD in Indonesia based on the discussion from 12 dermatological centers. Concurrent with the development of new drugs, this study aims to evaluate and develop a guideline for the treatment of seborrheic dermatitis in Indonesia to update the previous guidelines in 2017. Methods: Systematic review was based on evidence-based methods, and scientific evidences were acquired through systematic search. Evidence analysis was in accordance with the level of evidence. The available evidences were evaluated, and conclusion was based on the grade of recommendation.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Inflammation/Immunology
    Inflammation/Immunology The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency. www.MedChemExpress.com 1 Inflammation/Immunology Inhibitors & Modulators (+)-Borneol (+)-DHMEQ ((1R,2R,6R)-Dehydroxymethylepoxyquinomicin; (d-Borneol) Cat. No.: HY-N1368A (1R,2R,6R)-DHMEQ) Cat. No.: HY-14645A Bioactivity: (+)-Borneol (d-Borneol) is a natural bicyclic monoterpene used Bioactivity: (+)-DHMEQ is an activator of antioxidant transcription factor for analgesia and anesthesia in traditional Chinese medicine; Nrf2. (+)-DHMEQ is the enantiomer of (-)-DHMEQ. (-)-DHMEQ enhances GABA receptor activity with an EC50 of 248 μM. inhibits NF-kB than its enantiomer (+)-DHMEQ. Purity: 98.0% Purity: 98.02% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 100 mg 2 mg, 5 mg, 10 mg, 25 mg (-)-Epicatechin (-)-Ketoconazole ((-)-Epicatechol; Epicatechin; epi-Catechin) Cat. No.: HY-N0001 Cat. No.: HY-B0105B Bioactivity: (-)-Epicatechin inhibits cyclooxygenase-1 ( COX-1) with an Bioactivity: (-)-Ketoconazole is one of the enantiomer of Ketoconazole. Ketoconazole is a racemic mixture of two enantiomers, IC50 of 3.2 μM. (-)-Epicatechin inhibits the IL-1β-induced expression of iNOS by blocking the nuclear localization of the levoketoconazole ((2S,4R)-(−)-ketoconazole) and p65 subunit of NF-κB.
    [Show full text]
  • Seborrheic Dermatitis and Its Relationship with Malassezia Spp
    REVIEW Seborrheic dermatitis and its relationship with Malassezia spp Manuel Alejandro Salamanca-Córdoba†,1,2, Carolina Alexandra Zambrano-Pérez2,3, Carlos Mejía-Arbeláez2,4, Adriana Motta5, Pedro Jiménez6, Silvia Restrepo-Restrepo7, Adriana Marcela Celis-Ramírez1,8* Abstract Seborrheic dermatitis (SD) is a chronic inflammatory disease that that is difficult to manage and with a high impact on the individual’s quality of life. Besides, it is a multifactorial entity that typically occurs as an inflammatory response toMalassezia species, along with specific triggers that contribute to its pathophysiology. Sin- ce the primary underlying pathogenic mechanisms include Malassezia proliferation and skin inflammation, the most common treatment includes topical antifungal keratolytics and anti-inflammatory agents. However, the consequences of eliminating the yeast population from the skin, the resistance profiles ofMalassezia spp. and the effectivity among different groups of medications are unknown. Thus, in this review, we summarize the current knowledge on the disease´s pathophysio- logy and the role of Malassezia sp. on it, as well as, the different antifungal treatment alternatives, including topical and oral treatment in the management of SD. Key words: seborrheic dermatitis, Malassezia, pathogenic role, treatment. Dermatitis seborreica y su relación con Malassezia spp Resumen La dermatitis seborreica (DS) es una enfermedad inflamatoria crónica, con un elevado impacto en la calidad de vida del individuo. Además, DS es una entidad multifactorial que ocurre como respuesta inflamatoria a las levaduras del género Malassezia spp., junto con factores desencadenantes que contribuyen a la fisio- patología de la enfermedad. Dado que el mecanismo patogénico principal involucra la proliferación e inflamación generada por Malassezia spp., el tratamiento más usado son los agentes tópicos antifúngicos y antiinflamatorios.
    [Show full text]